Moderna CEO criticizes new Covid-19 vaccine policies

In the United States, during the WIRED Health summit, Moderna CEO Stéphane Bancel expressed concerns about new Covid-19 vaccine policies introduced by Health and Human Services Secretary Robert F. Kennedy, Jr. These changes mark a significant shift from previous recommendations, as the FDA now states that Covid vaccines should be prioritized for individuals at high risk of serious disease, specifically those aged 65 and older or individuals with other health conditions. The FDA previously recommended that anyone aged six months or older receive the vaccine. Bancel indicated that this new guidance complicates the vaccination process for families with at-risk members who can no longer easily access vaccines. While Moderna had recently received FDA approval for an updated version of its Covid-19 vaccine, which raised concerns over distribution logistics, the approval came alongside new restrictions that have proven contentious. As a result of the latest policy changes, some states now require prescriptions for Covid shots, reducing access for healthy individuals who previously could receive vaccinations freely at pharmacies. The backlash has caused various implications for public health strategies designed to combat the ongoing pandemic, which create apprehension, particularly for those wanting to protect vulnerable loved ones. In May 2025, Secretary Kennedy also terminated a significant $590 million contract with Moderna aimed at developing a bird flu vaccine, which heightened concerns about pandemic preparedness and the implications of shifting funding away from mRNA technology. There is rising scrutiny regarding the efficacy of mRNA vaccines, particularly in light of the FDA's new labeling requirements addressing risks like myocarditis and pericarditis, notably among young males post-vaccination. Furthermore, HHS is favoring older vaccine platforms, which raises questions about the future of mRNA research and development. Despite these regulatory challenges, Bancel remains optimistic about ongoing dialogue with the FDA. In addition to the developments related to Covid-19, Moderna has gained expanded approval for its RSV vaccine for adults aged 18 to 59 at risk of disease. Notably, the company's mRNA cancer therapies continue to progress, with several ongoing projects and expectations of FDA approvals. Bancel highlighted the use of mRNA technology in the fight against infectious diseases and cancer, maintaining that no vaccine has been studied more thoroughly for safety and efficacy than the mRNA vaccines currently available.